HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

clopidogrel (Plavix)

Subscribe to New Research on clopidogrel

RN given refers to cpd without isomeric designation

Also Known As:

Plavix; BMS brand 1 of clopidogrel bisulfate; BMS brand 2 of clopidogrel bisulfate; Iscover; PCR 4099; PCR-4099; SC 25989C; SC 25990C; SR 25989; clopidogrel bisulfate; clopidogrel, (+)(S)-isomer; methyl 2-(2-chlorophenyl)-2-(4,5,6,7-tetrahydrothieno(3,2-c)pyridin-5-yl)acetate

Networked: 4425 relevant articles (439 outcomes, 1141 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Angiolillo, Dominick J: 104 articles (01/2016 - 04/2004)
2.	Bhatt, Deepak L: 81 articles (10/2015 - 05/2002)
3.	Cannon, Christopher P: 74 articles (10/2015 - 10/2002)
4.	Gurbel, Paul A: 60 articles (06/2015 - 02/2003)
5.	Wallentin, Lars: 58 articles (10/2015 - 05/2003)
6.	Storey, Robert F: 55 articles (10/2015 - 09/2002)
7.	Montalescot, Gilles: 52 articles (11/2015 - 01/2004)
8.	Tantry, Udaya S: 49 articles (06/2015 - 01/2005)
9.	Harrington, Robert A: 47 articles (03/2015 - 09/2004)
10.	Kastrati, Adnan: 45 articles (07/2015 - 04/2002)

Related Diseases

1.	Stroke (Strokes) 09/14/2005 - "Overall, pretreatment with clopidogrel resulted in a highly significant reduction in cardiovascular death, MI, or stroke from randomization through 30 days (70 [7.5%] vs 112 [12.0%]; adjusted OR, 0.59 [95% CI, 0.43-0.81]; P = .001; number needed to treat = 23). " 01/01/2003 - "The MATCH trial is currently being conducted to test the hypothesis that long-term administration of clopidogrel on top of ASA is superior to clopidogrel alone for the reduction of major ischaemic events in patients with recent TIA or ischaemic stroke who are at high risk of atherothrombotic recurrence. " 02/01/2011 - "Clopidogrel use was associated with a non-significant reduction of perioperative stroke/death (4.3% vs. 2.4%; p = 0.13) and disabling stroke (1.2% vs. 1.0%; p = 1) rates. " 07/01/2006 - "Clopidogrel has not shown significant reduction in reoccurrence of stroke and has not been studied for patients with a previous TIA. " 11/01/2006 - "A prediction model which allows to identify patients in whom clopidogrel or dipyridamol plus ASA is superior to ASA for the secondary prevention of stroke is presented."
2.	Hemorrhage 02/01/2013 - "Presently, however, limiting the duration of triple therapy followed by clopidogrel and an oral anticoagulant seems the best option for the majority of patients to minimize bleeding risk without an increase in other adverse events." 04/01/2010 - "However, recent studies have suggested that there is large inter-individual response variability to these drugs (especially to clopidogrel) and that improved inhibition of platelet reactivity using higher doses or new, more potent agents would further reduce the occurrence of cardiovascular events, but may also increase the risk of bleeding. " 01/01/2015 - "These agents have a faster-acting, more-potent, and more-predictable antiplatelet effect than clopidogrel, which translates into improved clinical outcomes in patients with ACS, albeit at the expense of an increased risk of bleeding. " 03/01/2007 - "Lack of nonresponse and profound inhibition with clopidogrel allow for the maintenance of a delicate balance between proven efficacy and acceptable bleeding risks for long-term secondary prevention in outpatients after acute vascular events." 11/01/2014 - "In clinical studies enrolling patients with ACS these drugs decreased the incidence of ischemic events compared to the standard therapy with clopidogrel and ASA; however, this beneficial effect was associated with an increase in bleeding events. "
3.	Acute Coronary Syndrome 01/01/2006 - "Clopidogrel given for up to 1 year in patients undergoing PCI after presentation with acute coronary syndromes is a highly cost-effective treatment strategy." 04/01/2012 - "Based on their beneficial results in comparison to clopidogrel, these agents have found their way into the recent international guidelines for treatment of patients with acute coronary syndromes. " 02/01/2010 - "Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes." 07/01/2010 - "Higher clopidogrel doses have been associated with improved clinical outcomes, especially in those presenting with acute coronary syndrome. " 03/01/2007 - "One-year treatment with clopidogrel is a cost-effective treatment option in patients with acute coronary syndrome from the perspective of a third-party payer in Germany."
4.	Myocardial Infarction 07/04/2006 - "Clopidogrel was also associated with a significant reduction in the odds of an in-hospital death or myocardial infarction in patients who achieved partial (OR 0.30, p = 0.003) or complete STRes at 90 min (OR 0.49, p = 0.056), whereas clinical benefit was not apparent in patients who had no STRes (OR 0.98, p = 0.95) (p for interaction = 0.027). " 01/01/2006 - "After ACS with non-ST-elevation myocardial infarction the combined therapy with ASA and clopidogrel gives a better outcome than ASA alone. " 09/14/2005 - "To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. " 12/01/2011 - "The aim of this study was to investigate whether clopidogrel loading before arrival at the PCI centre may result in an improved outcome of primary PCI for ST-elevation myocardial infarction (STEMI). " 01/01/2011 - "Recent studies have raised concerns that interaction of PPIs and clopidogrel could reduce the efficacy of clopidogrel and thus increase events such as myocardial infarction. "
5.	Thrombosis (Thrombus) 04/01/2005 - "Because of its central role in the formation and stabilization of a thrombus, the P2Y (12) receptor is a well-established target of antithrombotic drugs such as clopidogrel, which has proven efficacy in many clinical trials and experimental models of thrombosis. " 08/15/2009 - "The results of the VASP-P assay did not correlate with the presence of ST. In conclusion, patients who experienced DES thrombosis demonstrated significantly greater rates of clopidogrel resistance as determined by P2Y12 reaction units, but not VASP-P, compared with patients without DES thrombosis. " 11/01/1995 - "Clopidogrel may be beneficial in the prevention of arterial thrombosis." 01/01/2015 - "This study protocol amendment was made in response to a large trial demonstrating that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. " 01/01/2009 - "Recently a placebo-controlled trial has shown that clopidogrel is effective in safely preventing primary AVF thrombosis, but ineffective at increasing functional patency. "

Related Drugs and Biologics

1.	Aspirin (Acetylsalicylic Acid)
2.	prasugrel
3.	Ticagrelor
4.	Ticlopidine (Ticlid)
5.	Dipyridamole (Persantine)
6.	Platelet Aggregation Inhibitors (Antiplatelet Drugs)
7.	Warfarin (Coumadin)
8.	Adenosine Diphosphate (ADP)
9.	thienopyridine
10.	Heparin (Liquaemin)

Related Therapies and Procedures

1.	Stents
2.	Transplants (Transplant)
3.	Coronary Artery Bypass (Coronary Artery Bypass Surgery)
4.	Drug-Eluting Stents
5.	Angioplasty (Angioplasty, Transluminal)